Share 'ReveraGen BioPharma Inc initiates VISION-DMD Phase 2a Study for Treatment of Duchenne'
PPMD is excited to see the continued progress of vamorolone (VBP-15), with enrollment in the VISION-DMD Phase 2a Study now beginning. PPMD is proud to be an early funder of vamorolone and are hopeful that this compound will one day prove to be an alternative option for steroids.
Read the Press Release from ReveraGen:
ReveraGen BioPharma Inc initiates VISION-DMD Phase 2a Study for Treatment of Du…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this